Clinical trial
Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2…
NCT00284180 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00284180 |
|---|---|
| Title | Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer |
| Official title | Phase II Trial of Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Breast Cancer |
| Intervention type | Drug |
| Interventions | Vinflunine, Trastuzumab |
| Enrollment | 32 |
| Start date | Jan 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Nov 1, 2010 |
| First posted | Jan 31, 2006 |
| Last update posted | Aug 9, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: